15,086 research outputs found
The Recommended Dose with Ray Moynihan
No full textMulti-award-winning journalist and health researcher Dr Ray Moynihan of Bond University's Centre for Research in Evidence-Based Practice (CREBP) today launched a compelling new podcast series produced by one of the world’s largest and most trusted independent health research organisations., Cochrane AustraliaThe Recommended Dose tackles the big questions in health and explores the insights, evidence and ideas of extraordinary researchers, thinkers, writers and health professionals from around the globe.Produced by Cochrane Australia and co-published with the BM
Who benefits from treating prehypertension?
No full textWith a drug company funded conference on prehypertension set to take place next year, Ray Moynihan examines the emergence of this controversial new classificatio
FDA fails to reduce accessibility of paracetamol despite 450 deaths a year
No full textConfidential documents from the US Food and Drug Administration suggest that the agency has avoided a debate on tough new measures to reduce overdoses from painkillers—to avoid offending the pharmaceutical industry. Ray Moynihan reports from Washington,
Doctors’ education: The invisible influence of drug company sponsorship
No full textAs calls to end drug companies’ direct sponsorship of doctors’ education echo round the world, an investigation in Australia reveals sponsor involvement in the education of thousands of general practitioners, writes Ray Moynihan.</p
Disease mongering is now part of the global health debate.
No full textRay Moynihan and colleagues, who organized the world's first international conference on disease mongering in 2006, discuss its subsequent impact
Selling sickness: the pharmaceutical industry and disease mongering
No full textA lot of money can be made from healthy people who believe they are sick. Pharmaceutical companies sponsor diseases and promote them to prescribers and consumers. Ray Moynihan, Iona Heath, and David Henry give examples of "disease mongering" and suggest how to prevent the growth of this practic
[Letter from Alex Bradford to Lieutenant and Mrs. Ray Starner - November 4, 1940]
No full textLetter from Alex Bradford to Lieutenant and Mrs. Ray Starner describing the the current state of affairs that the author was experiencing, including: the London blitz, the moral of the troops on the ground, and the collective company of men opposing the Nazi regime
Can the relationship between doctors and drug companies ever be a healthy one?
No full textThe financial ties between doctors and drug companies have come under intense scrutiny in recent years. Some commentators--such as Marcia Angell, former editor-in-chief of the New England Journal of Medicine--argue that the mission of doctors is fundamentally different to the mission of drug companies and that the ties between them should be completely cut. "Drug companies are investor owned businesses with a responsibility to maximise profits for their shareholders," says Angell. "That is quite different from the mission of the medical profession, which is to provide the best care possible for patients." Other commentators have argued that clinicians and drug companies do have some shared goals in aiming to maximize human health. In this debate, Emma D'Arcy, co-founder of a social networking site that facilitates interactions between doctors and drug companies, argues that it would be valuable to the public if we could establish "authentic alliances" between these professionals. But journalist Ray Moynihan argues that such alliances are prone to the corrupting influence of pharmaceutical industry money, and that disentanglement is a healthier alternative
Using Evidence to Combat Overdiagnosis and Overtreatment: Evaluating Treatments, Tests, and Disease Definitions in the Time of Too Much
No full textRay Moynihan and colleagues outline suggestions for improving the way that medical evidence is produced, analysed, and interpreted to avoid problems of overdiagnosis and overtreatment. Please see later in the article for the Editors' Summar
- …
